What the studies show
DREAMS-1 and DREAMS-2 in type 2 diabetes met their HbA1c endpoints; approved for glycaemic control in China on that basis. DREAMS-3 reported superiority to semaglutide on HbA1c and weight.
Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.
- 1Innovent. Mazdutide received approval from China's NMPA for chronic weight management; DREAMS programme in type 2 diabetes.Press releases, 2025Approval 27 June 2025.
In context
Mazdutide is a once-weekly GLP-1/glucagon dual agonist developed by Innovent with Lilly. In the 610-person GLORY-1 trial, published in the New England Journal of Medicine in May 2025, it produced 14.8% weight loss at 48 weeks on 6 mg against 0.5% on placebo; a 9 mg dose reached 18.6% at 60 weeks in GLORY-2. China's regulator approved it for chronic weight management on 27 June 2025 and later for type 2 diabetes. It is not approved in the US, EU or UK.
Mazdutide is approved in china only. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Mazdutide proven to help with blood glucose?
What studies are behind the grade?
Is Mazdutide approved for this?
Other outcomes for Mazdutide
- ABody weight2 phase 3 RCTs
- BLiver fatPhase 3 sub-analyses
- AGI side effectsadversePhase 3
Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →